Additionally, the 36-month beta value for PTCT is 0.65. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 5 rating it as “hold,” and 1 rating it as “sell.”
The public float for PTCT is 74.40M and currently, short sellers hold a 7.02% ratio of that float. The average trading volume of PTCT on September 27, 2024 was 609.18K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PTCT) stock’s latest price update
The stock of PTC Therapeutics Inc (NASDAQ: PTCT) has increased by 2.78 when compared to last closing price of 36.64. Despite this, the company has experienced a 4.15% gain in its stock price over the last five trading sessions. prnewswire.com reported 2024-09-26 that WARREN, N.J., Sept. 26, 2024 /PRNewswire/ — PTC Therapeutics (NASDAQ: PTCT) announced today that the FDA has granted Fast Track designation to the PTC518 program for the treatment of Huntington’s disease.
PTCT’s Market Performance
PTC Therapeutics Inc (PTCT) has experienced a 4.15% rise in stock performance for the past week, with a 6.63% rise in the past month, and a 8.66% rise in the past quarter. The volatility ratio for the week is 3.73%, and the volatility levels for the past 30 days are at 4.34% for PTCT. The simple moving average for the past 20 days is 9.94% for PTCT’s stock, with a 21.60% simple moving average for the past 200 days.
Analysts’ Opinion of PTCT
Many brokerage firms have already submitted their reports for PTCT stocks, with Robert W. Baird repeating the rating for PTCT by listing it as a “Outperform.” The predicted price for PTCT in the upcoming period, according to Robert W. Baird is $44 based on the research report published on September 04, 2024 of the current year 2024.
UBS, on the other hand, stated in their research note that they expect to see PTCT reach a price target of $47. The rating they have provided for PTCT stocks is “Buy” according to the report published on August 26th, 2024.
PTCT Trading at 12.22% from the 50-Day Moving Average
After a stumble in the market that brought PTCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.45% of loss for the given period.
Volatility was left at 4.34%, however, over the last 30 days, the volatility rate increased by 3.73%, as shares surge +7.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.15% upper at present.
During the last 5 trading sessions, PTCT rose by +4.15%, which changed the moving average for the period of 200-days by +42.71% in comparison to the 20-day moving average, which settled at $34.38. In addition, PTC Therapeutics Inc saw 36.65% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PTCT starting from Gravier Pierre, who sale 2,269 shares at the price of $34.02 back on Jul 16 ’24. After this action, Gravier Pierre now owns 53,531 shares of PTC Therapeutics Inc, valued at $77,200 using the latest closing price.
ZELDIS JEROME B, the Director of PTC Therapeutics Inc, sale 20,000 shares at $38.24 during a trade that took place back on May 22 ’24, which means that ZELDIS JEROME B is holding 14,500 shares at $764,800 based on the most recent closing price.
Stock Fundamentals for PTCT
Current profitability levels for the company are sitting at:
- -0.22 for the present operating margin
- 0.78 for the gross margin
The net margin for PTC Therapeutics Inc stands at -0.53. The total capital return value is set at -0.15.
Based on PTC Therapeutics Inc (PTCT), the company’s capital structure generated -0.44 points at debt to capital in total, while cash flow to debt ratio is standing at -0.38. The debt to equity ratio resting at -0.31. The interest coverage ratio of the stock is -1.93.
Currently, EBITDA for the company is -112.81 million with net debt to EBITDA at 5.1. When we switch over and look at the enterprise to sales, we see a ratio of 2.93. The receivables turnover for the company is 4.81for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.23.
Conclusion
In conclusion, PTC Therapeutics Inc (PTCT) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
